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Abstract: The fight against infectious diseases is probably one of the greatest public health challenges 
faced by our society, especially with the emergence of carbapenem-resistant gram-negatives that are in 
some cases pan-drug resistant. Currently, -lactamase-mediated resistance does not spare even the 
newest and most powerful -lactams (carbapenems), whose activity is challenged by carbapenemases. 
The worldwide dissemination of carbapenemases in gram-negative organisms threatens to take medi-
cine back into the pre-antibiotic era since the mortality associated with infections caused by these “su-
perbugs” is very high, due to limited treatment options. Clinically-relevant carbapenemases belong either to metallo--
lactamases (MBLs) of Ambler class B or to serine--lactamases (SBLs) of Ambler class A and D enzymes. Class A car-
bapenemases may be chromosomally-encoded (SME, NmcA, SFC-1, BIC-1, PenA, FPH-1, SHV-38), plasmid-encoded 
(KPC, GES, FRI-1) or both (IMI). The plasmid-encoded enzymes are often associated with mobile elements responsible 
for their mobilization. These enzymes, even though weakly related in terms of sequence identities, share structural fea-
tures and a common mechanism of action. They variably hydrolyse penicillins, cephalosporins, monobactams, carbap-
enems, and are inhibited by clavulanate and tazobactam. Three-dimensional structures of class A carbapenemases, in the 
apo form or in complex with substrates/inhibitors, together with site-directed mutagenesis studies, provide essential input 
for identifying the structural factors and subtle conformational changes that influence the hydrolytic profile and inhibition 
of these enzymes. Overall, these data represent the building blocks for understanding the structure-function relationships 
that define the phenotypes of class A carbapenemases and can guide the design of new molecules of therapeutic interest. 
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1. INTRODUCTION 
-Lactams have been the most successful antimicrobial 
agents since the beginning of the antibiotic era due largely to 
their unique combination of efficacy, safety and versatility. 
-lactams remain the workhorses for the treatment of several 
infections (from mild community-acquired infections to se-
vere life-threatening nosocomial infections), either alone or 
in combination regimens [1]. The expanded-spectrum cepha-
losporins and the carbapenems, in particular, still represent a 
major treatment option for serious infections caused by 
gram-negative bacteria, and are listed among the drugs of 
choice in guidelines for the empiric treatment of several in-
fections [2]. 
The expanding problem of resistance to -lactam antibi-
otics illustrates the genetic adaptability of bacterial popula-
tions over a relatively short period of time. -Lactamase-
mediated resistance to -lactams may result from selection of 
bacterial species that naturally produced -lactamases, from 
mutation either in structural genes of their regulatory com-
ponents or from acquisition of specific resistance genes. 
 
*Address correspondence to this author at the Service de Bactériologie-
Hygiène, Hôpital de Bicêtre, APHP, EA7361, Faculté de Médecine Paris-
Sud, LabEx LERMIT, Le Kremlin-Bicêtre, France; Tel/Fax: +33-1-4521-
2986, +33-1-4521-6340; E-mail: thierry.naas@bct.aphp.fr. 
Based on the genetic environment and on its genetic sup-
port, -lactamases may be produced in a constitutive or in-
ducible manner [3]. Plasmids and transposons, in particular, 
play an important role for rapid diffusion of those genes. 
From a clinical point of view, selection of -lactamases with 
extended-spectrum activity has been observed in gram-
negatives (Enterobacteriaceae, Pseudomonas spp., Acineto-
bacter spp.) but not in gram-positives (Staphylococcus, En-
terococcus spp.) [4]. -lactamases play an important role in 
acquired resistance to -lactams in Enterobacteriaceae 
whereas in Pseudomonas aeruginosa and Acinetobacter 
baumannii other mechanisms are often associated such as 
impermeability and overexpression of efflux pumps [2, 5-7]. 
In gram-negative pathogens the major mechanism of ac-
quired -lactam resistance is the production of -lactamases; 
other mechanisms (e.g. impermeability, active efflux, PBP 
target modification) also contribute in several cases. On the 
basis of their amino acid sequences and catalytic mecha-
nisms, -lactamases are divided into 4 molecular classes. 
Classes A, C and D contain active-site serine -lactamases 
(SBLs) whose reaction pathways involve acyl-enzyme ad-
ducts while class B contain metallo--lactamases (MBLs), 
which do not form such intermediates [8]. The introduction 
of new -lactam classes has always led to the emergence of 
-lactamases capable of degrading them, and the evolution 
of -lactamases has been a major driving force for -lactam 
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discovery and development. While a handful of -lactamases 
were known in the early 1970’s, the number since then in-
creased exponentially. Currently, -lactamase-mediated re-
sistance does not spare even the newest and most powerful 
-lactams (i.e. the expanded-spectrum cephalosporins and 
carbapenems), whose activity is challenged by the extended-
spectrum -lactamases (ESBLs, classes A, C and D), the 
metallo--lactamases (MBLs, class B), and the serine-
carbapenemases (classes A and D) [2]. 
Most of the clinically-relevant -lactamases belong to the 
Ambler class A serine-active -lactamases. They operate via 
a multistep process involving the formation of an intermedi-
ate acyl-enzyme and its subsequent hydrolytic destruction 
(Fig. 1) [9-11]. The steady state kinetic parameters are made 
of different combinations of microscopic rate constants [11, 
12]. Every -lactamase is thus defined for each substrate by : 
(i) the turnover number, « kcat », which is the best parameter 
to describe the hydrolytic activity of -lactamases, since it 
depends on the rates of formation and hydrolysis of the acyl–
enzyme complex (Fig. 1); (ii) the apparent affinity or half-
saturation constant, Km that is frequently referred to as the 
Michaelis constant because of its equivalence to the half-
saturation constant defined for the Michaelis–Menten 
mechanism (which does not, however, include a covalent 
intermediate). The Km includes all the rate constants describ-
ing the catalytic steps of -lactam hydrolysis; and (iii) the 
apparent second-order rate constant, frequently called ‘cata-
lytic efficiency’, kcat Km, has also been used as to character-
ize -lactamases. Class A enzymes (known primarily as 
penicillinases) tend to hydrolyze penicillins over cepha-
losporins as substrates although many variants may signifi-
cantly hydrolyze broad-spectrum cephalosporins and also a 
few carbapenems [13, 14]. Most class A -lactamases are 
inhibited by the clinically-available -lactamase inhibitors, 
such as clavulanic acid, tazobactam and sulbactam [15]. 
Class A -lactamases are either naturally-produced and 
chromosome-encoded or acquired and often plasmid-
encoded.  
The dissemination of class A carbapenemases among 
Enterobacteriaceae is a matter of great clinical concern 
given (i) the major role of these pathogens as causes of 
nosocomial infections (and, for Escherichia coli, also of 
community-acquired infections), and (ii) the major role of 
expanded-spectrum cephalosporins and carbapenems in the 
treatment of those infections [2]. This review will focus on 
the clinically-relevant class A carbapenemases and address 
structure-function relationships, a prerequisite for the de-
sign, in a near future, of novel inhibitors of this class of 
carbapenemases. 
2. EPIDEMIOLOGY OF CLASS A CARBAPENE-
MASES 
Class A carbapenemases may be chromosomally-
encoded (SME, NmcA, SFC-1, BIC-1, PenA, FPH-1, SHV-
38), plasmid-encoded (KPC, GES, FRI-1) or both (IMI). 
Chromosomally-encoded class A carbapenemases have been 
identified in rare gram-negative species that appeared spo-
radically in clinical or environmental samples since their first 
discovery, more than 20 years ago [13, 16]. Some have been 
detected in rare Enterobacter cloacae, Serratia marcescens, 
Serratia fonticola or Pseudomonas fluorescens as single iso-
lates or in small outbreaks [13, 16] while others are linked to 
the species such as PenA and FPH-1 present in Burkholderia 
cepacia and Francisella philomiragia, respectively. On the 
other hand plasmid-encoded enzymes, best exemplified by 
KPC-2, have spread all around the world and have been iso-
lated in most of the clinically-relevant enterobacterial spe-
cies, P. aeruginosa and A. baumannii [2, 17]. Usually, class 
A carbapenemases confer reduced susceptibility to imipenem 
to bacteria expressing them, but minimal inhibitory concen-
trations (MICs) can remain in the susceptibility range (e.g., 
imipenem MICs of < 2 g/ml). Routine susceptibility testing 
may therefore not detect these isolates as carbapenemase 
producers. The mechanism of hydrolysis involves an active-
site serine at position 70 of the Ambler class A numbering 
scheme [18]. Class A carbapenemases have the ability to 
hydrolyze a broad variety of -lactams, including carbap-
enems, cephalosporins, penicillins, and aztreonam, and are 
more or less inhibited by clavulanate and tazobactam, plac-
ing them in the 2f functional subgroup of -lactamases [19, 
20]. 
2.1. Naturally- and chromosomally-encoded class A car-
bapenemases 
2.1.1. SME and IMI/NmcA 
Class A carbapenemases that belong to the SME and 
IMI/NmcA families are known from tiny numbers of Serra-
tia and Enterobacter isolates [24, 26, 37]. Carbapenem resis-
tance is evident in the IMI/NmcA or SME producing organ-
isms but they usually remain susceptible to expanded-
spectrum cephalosporins. In addition, they differ from many 
plasmid-encoded carbapenemase-producing pathogens in 
that they generally remain susceptible to all other non--
lactam antibiotic families (fluoroquinolones, aminoglyco-
sides, …).  
SME-1, which stands for “Serratia marcescens enzyme”, 
was initially detected in two S. marcescens isolates collected 
in England in 1982 [24, 38]. The SME variants that differ 
only by one or two amino acid substitutions have so far 
 
Fig. (1). General catalytic pathway of active-site serine -lactamases. This mechanism is schematically represented by a three-step model. E 
is the enzyme. 
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Fig. (2). Phylogeny of several chromosomally- and plasmid-encoded class A -lactamases. For naturally-occurring class A -lactamases, the 
bacterial host name is indicated. The carbapenemases are highlighted in bold. The dendrogram was constructed with FigTree [21] using 
ClustalW [22] aligned protein sequences. The references of all these enzymes can be found in the Beta-Lactamase DataBase at 
http://www.bldb.eu/BLDB.php?class=A. 
exclusively been found in S. marcescens. SME-producing 
isolates have been infrequently and sporadically detected in 
the UK, across USA, Argentina, Switzerland and Canada 
[24, 39-45]. SME producing S. marcescens were found as 
single or small clusters of up to 19 isolates [44]. Pulsed-field 
gel electrophoresis (PFGE) revealed a great genetic variabil-
ity among SME-producing S. marcescens isolates collected 
from different geographical locations, although some degree 
of clonal spread was evidenced when several isolates were 
collected from one location [13, 41]. The blaSME gene is not 
present in all S. marcescens isolates, but only a small sub-
population of the species. Of note, an increasing identifica-
tion of S. marcescens harbouring blaSME gene has been de-
scribed in North and South America [44]. 
IMI/NmcA enzymes (IMIpenemase/Non-metallo-
carbapenemaseA), which form two subgroups, IMI and 
NmcA, respectively [26, 37, 46] have been detected in rare 
clinical isolates of E. cloacae in the United States, France, 
Tahiti (French Polynesia), Finland, Ireland, and Argentina 
[26, 37, 47-51]. NmcA and IMI-1 share 97% amino acid 
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identity and are related to SME-1, with approximately 70% 
amino acid identity. The chromosomally-encoded NmcA 
enzyme was initially reported in 1994 in an E. cloacae iso-
late from France [37]. Since then, it has been identified in 
rare cases in Finland, Argentina, USA [47, 48, 52]. The 
chromosomally-located blaIMI-1 gene was initially reported in 
two E. cloacae isolates from the USA in 1996 [26]. Plasmid-
encoded blaIMI-2 gene was subsequently detected in clonally-
related E. asburiae isolates recovered from 7 out of 16 rivers 
in the mid-western regions of the USA [34], and in an E. 
cloacae clinical isolate from China [53]. IMI carbapene-
mases are relatively uncommon but their presence in Entero-
bacter clinical isolates have increasingly been reported in 
recent years in France, Finland, Singapore, Croatia and Ire-
land [49, 52, 54-56]. They consist mainly of E. cloacae iso-
lates producing the IMI-1 enzyme or single amino acid vari-
ant IMI-3 [57]. However, IMI-producing E. asburiae clinical 
isolates have also been found in three patients from different 
cities in France between 2007 and 2011 [58] and in Ireland 
[49]. In Finland, IMI-positive E. cloacae were found in 2008 
and 2010 [52]. Nine IMI-variants have been described, 3 
published (IMI-1-3) from the USA, France, Finland, Singa-
pore, Ireland and China, 3 (IMI-4,7,8) sequences are avail-
able on GenBank, and three (IMI-5,6,9) are assigned on La-
hey Clinic website but not yet released. They differ by 1 to 7 
amino acid substitutions from IMI-1, except for IMI-8, re-
cently identified in the UK that has 42 amino acid changes 
(85% amino acid identity). 
2.1.2. The SFC-1 Enzymes 
SFC-1 was identified from S. fonticola. The gene coding 
for this carbapenemase was chromosomally-encoded [59, 
60]. The SFC-1 is not ubiquitous in S. fonticola. It was only 
isolated sofar from a single S. fonticola environmental isolate 
from Portugal. SFC-1 is related to other class A carbapene-
mases, in particular KPC-2 from K. pneumoniae (64 % iden-
tity), NmcA (60 %), IMI-1 (60 %) and SME-1 (59 %) [24, 
26, 35, 37]. No putative LysR-type regulator gene was iden-
tified upstream of the blaSFC-1 gene, whereas such regulators 
are present upstream of blaNmcA, blaSME-1, and bla IMI-1 genes 
[26, 37, 61]. 
2.1.3. The SHV-38 Enzyme 
SHV-38 was isolated from K. pneumoniae isolate dis-
playing reduced susceptibility to imipenem. Its gene was 
chromosomally-encoded [33]. The SHV-38 enzyme differs 
by a single substitution, Ala146Val substitution (Ambler 
numbering [18]), from the broad-spectrum and naturally-
occurring -lactamase SHV-1. Recently, another SHV-38-
producing K. pneumoniae clinical isolate was identified from 
Brazil [62]. 
2.1.4. BIC-1 
BIC-1 carbapenemase was identified in an environmental 
Pseudomonas fluorescens isolate (PF-1) resistant to carbap-
enems and recovered from water of the Seine river in Paris 
(France) [30]. The blaBIC-1 gene was chromosomally-
encoded in P. fluorescens PF-1. BIC-1 has 69% and 63% 
amino acid identities with -lactamases SFC-1 from S. fonti-
cola and the plasmid-encoded KPC-2, respectively. It was 
further identified in two other P. fluorescens isolates 3 
months later again from water of the Seine river (Paris, 
France). 
2.1.5. FPH-1 
FPH-1 carbapenemase was recently characterized from 
Francisella philomiragia [31]. FPH-1 shares 77% amino 
acid sequence identity with the FTU-1, a non carbapenem-
hydrolyzing -lactamase from F. tularensis, which is intrin-
sic in this species [63]. FTU-1 and FPH-like proteins have 
been found in all F. tularensis and F. philomiragia isolates, 
respectively sequenced to date, suggesting that these -
lactamases may be naturally-present in the genus Fran-
cisella. These enzymes form a new and distinct branch of the 
class A -lactamase tree (Fig. 2). Despite their amino acid 
sequence homologies and their belonging to the genus Fran-
cisella, they display different antibiotic resistance profiles. 
The FTU-1 -lactamase confers a narrow-spectrum of resis-
tance to -lactams, limited mainly to penicillins. In contrast, 
FPH-1 confers a much broader-spectrum of resistance, in-
cluding expanded-spectrum cephalosporins, aztreonam and 
carbapenems. Unlike FTU-1, which elevates the MIC of 
imipenem 2-fold exclusively, FPH-1 elevates the MICs of 
imipenem, meropenem, ertapenem, and doripenem 8- to 64-
fold. The abilities of two closely related enzymes from the 
genus Francisella, FTU-1 and FPH-1, to confer distinct anti-
biotic resistance profiles represent another example of the 
evolutionary plasticity of class A -lactamases [31, 63]. 
2.1.6. PenA 
PenA is an inhibitor-resistant carbapenemase, most simi-
lar to KPC-2 found in Burkholderia multivorans, an oppor-
tunistic nosocomial pathogen, primarily infecting patients 
with cystic fibrosis. Phylogenetic comparisons revealed that 
PenA is highly related (71% similarity and 62% identity) to 
PenI (also reported as BPS-1d [64]), a native ESBL of B. 
pseudomallei, the causative agent of melioidosis [65]. PenA 
possesses peculiar properties, in the sense that it can hydro-
lyze inhibitors as well as all classes of -lactams (i.e. penicil-
lin, cephalosporins, monobactams, and carbapenems). This is 
worrisome, since -lactam antibiotics are recommended as a 
treatment option for infections due to B. cepacia complex 
and B. pseudomallei and that PenA--lactamase inhibitors 
are not available. These related bacterial species express 
closely related class A -lactamases that confer distinct anti-
biotic resistance profiles. 
2.2. Acquired Class A Carbapenemases (Plasmid-
Encoded Enzymes) 
2.2.1. IMI-2 Enzyme 
Unlike IMI-1/NmcA enzymes that are chromosomally-
encoded, IMI-2 is so far the only variant that is plasmid-
encoded in clonal E. asburiae isolates recovered from sev-
eral midwestern rivers of the USA [34], and from three iso-
lates identified from patients that had been in contact with an 
aquatic environment in distantly located French cities, and in 
clinical E. cloacae isolates from China and France [53, 58] 
(T. Naas, pers. com.). In addition, a carbapenem-resistant  
E. coli strain carrying the carbapenemase blaIMI-2 gene lo-
cated on a similar conjugative plasmid was described in 
Spain [66], suggesting transfer to other enterobacterial species. 
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With the increased use of carbapenems, it is likely that the 
isolation of IMI-2-producing Enterobacter spp isolates may 
increase, thus increasing the risk of transmission of the 
plasmid carrying blaIMI-2 gene to bacterial species responsible 
of nosocomial infections. 
2.2.2. FRI-1 Enzyme 
FRI-1 carbapenemase was identified in a carbapenem-
resistant E. cloacae DUB recovered from a rectal swab sam-
ple of a patient hospitalized in France [67]. This isolate was 
resistant to penicillins, 1st and 2nd generation cephalosporins, 
aztreonam and carbapenems, but remained susceptible to 3rd 
generation cephalosporins. FRI-1 shares 51-55% amino acid 
sequence-identity with the other class A carbapenemases but 
branches off the NmcA/IMI/SME-1 segment. The blaFRI-1 
gene was located on a ca. ~ 150 kb untypeable and non self-
transferable plasmid carrying no other antibiotic resistance 
determinant. A gene encoding a putative LysR type regulator 
was identified upstream of blaFRI-1 gene as observed upstream 
the blaNmcA/IMI-2 and blaSME carbapenemase genes. 
2.2.3. The KPC Enzymes 
The KPC (Klebsiella pneumoniae carbapenemase) is the 
most worrisome functional group 2f carbapenemases be-
cause of its location on self-conjugative plasmids, and its 
frequent association with K. pneumoniae, an organism noto-
rious for its ability to accumulate and transfer resistance de-
terminants. The first member of the KPC family was discov-
ered through the ICARE surveillance project in a K. pneu-
moniae clinical isolate from North Carolina in 1996 [35]. 
The geographical distribution of these enzymes in Entero-
bacteriaceae in general and especially in K. pneumoniae was 
limited until 2005 to the eastern part of the United States 
[68], where KPC-producing K. pneumoniae isolates are now 
frequently identified among nosocomial pathogens and in 
systemic infections [2, 17]. Within a few years, KPC pro-
ducers went global and were described in the North and 
South American countries, in Greece, in Italy, in Israel and 
in China, where they can be considered as endemic [2]. KPC 
producers and hospital outbreaks have been described in 
many European countries and in the Americas. Currently, 
KPC producers are identified in increasing numbers of coun-
tries and very rapidly alarming reports indicate extensive 
spread in most of the cases linked to direct transfer of hospi-
talized patients [69]. They have been reported mostly from 
hospital-acquired K. pneumoniae isolates, but KPC-
producing E. coli and other enterobacterial species have also 
been described. KPC-producing P. aeruginosa and A. bau-
mannii are increasingly reported [2, 17, 70-73]. Until now, 
KPC-producing A. baumannii are still restricted to Puerto 
Rico [72]. In K. pneumoniae the worldwide spread of the 
blaKPC genes is currently linked to a single clone (ST-258) 
but within a given geographical location, several KPC clones 
are disseminating, differing by Multi Locus Sequence Typ-
ing (MLST) type, by additional -lactamase content, by size, 
number and structure of plasmids. Despite of this genetic 
diversity, the blaKPC genes are generally associated to a sin-
gle genetic element: Tn4401, a 10-kb Tn3-type transposon 
[74, 75]. The clonal spread seen in several epidemics under-
scores the difficulties in outbreak management even with 
reinforced infection control measures. The most worrisome 
with these organisms is the multi-drug resistance, leaving 
very few, if any, treatment options, which results in high 
mortality rates [17]. 
SFC-1 carbapenemase from S. fonticola is the nearest 
phylogenetically-related enzyme of KPC (Fig. 2), with an 
amino acid sequence identity of 64% (Table 1). Even though 
the name KPC refers to the species in which the KPC-2 en-
zymes were originally identified, they have also been found 
in several other enterobacterial species, in P. aeruginosa and 
in A. baumannii. Among the 22 KPC-variants assigned to 
date, the sequences of 19 of them are available and clearly 
show a low degree of diversity (1 to 5 amino acid differ-
ences). For KPC-14, a two amino acid deletion has been 
identified (Table 5). The increasing number of variants and 
the increasing reports regarding their occurrence in environ-
mental samples signal the ongoing dispersion of this kind of 
Table 1. Sequence identity matrix for representative class A carbapenemases.
#
 
 BIC-1 SFC-1 KPC-2 NmcA IMI-2 SME-1 FRI-1 PenA GES-2 FPH-1 
BIC-1 100 69 63 56 56 57 52 48 37 28 
SFC-1  100 64 60 60 59 54 49 36 32 
KPC-2   100 55 55 56 53 53 38 30 
NmcA    100 97 70 56 45 35 32 
IMI-2     100 70 56 45 35 33 
SME-1      100 54 44 39 31 
FRI-1       100 43 35 29 
PenA        100 38 29 
GES-2         100 25 
FPH-1          100 
# Generated with ClustalW [22] 
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enzymes [76]. KPC-producing isolates have been recovered 
from rivers located in Portugal and Brazil, as well as from 
sewage samples in China, Brazil, and Austria [77-81]. 
2.2.4. The GES Enzymes 
GES-type enzymes (also named IBC) are increasingly 
reported in gram-negative rods, including in P. aeruginosa, 
A. baumannii, E. coli, and K. pneumoniae [2, 14]. The GES-
1 -lactamase (for “Guiana extended spectrum”) was first 
described in 2000 in a K. pneumoniae clinical isolate from 
French Guiana [83] and subsequently, a point mutant deriva-
tive, named IBC-1 (for “integron-borne cephalosporinase”), 
was isolated from an E. cloacae isolate in Greece [82]. This 
confusing situation has led to several revisions of the GES 
family nomenclature in which the IBC names have been 
converted to the GES nomenclature [14, 84]. BEL-1 ESBL 
from P. aeruginosa is the closest phylogenetically-related -
lactamase of the GES family members with an amino-acid 
sequence identity of 50% [85]. GES enzymes are only dis-
tantly related to the other class A carbapenemases (Fig. 2), 
with identities of 38 % to KPC-2, 39 % to SME-1, and 35 % 
to NmcA (Table 1). GES family members differ from each 
other by one to four amino acid substitutions. The number of 
GES-variants known (23, see Table 6) is increasing rapidly, 
signaling the current worldwide spread of these enzymes. 
GES-2 was from South Africa, GES-5, GES-6, GES-7 and 
GES-8 from Greece, and GES-3 and GES-4 from Japan [82, 
86-89]. Among the 23 known GES variants (Table 6) eleven 
with either Gly170Asn or Gly170Ser mutations display car-
bapenemase activity. The other GES variants are categorised 
as ESBLs without any carbapenem-hydrolysing activity. One 
of them, GES-14, has extended its spectrum towards carbap-
enems, aztreonam and cephamycins and has reduced suscep-
tibility towards inhibitors [90]. These enzymes are worri-
some, since extensive use of carbapenems to treat ESBL 
infections may select for GES-variants capable of hydrolyz-
ing sufficiently carbapenems with a low susceptibility to 
commercially available inhibitors. On the opposite, it was 
recently demonstrate that antibiotic pressure with cefotaxime 
or aztreonam was not able to select resistance to imipenem 
[91]. The number of point-mutant derivatives of GES-
enzymes and their geographic spread signals an ongoing 
evolution for this family of enzymes. The emergence of 
GES-type ESBLs sheds a very dark light on the overall pic-
ture of antibiotic resistance, as these enzymes may become 
true carbapenemases by single point mutations. 
Although rare, GES carbapenemases have now been 
identified worldwide, most frequently associated with single 
occurrences, in Greece, France, Portugal, South Africa, 
French Guiana, Brazil, Argentina, Korea, USA, Canada, 
China, Belgium and Japan [14, 92]. However, several out-
breaks of GES-producing gram-negative bacteria have been 
described: K. pneumoniae in Korea, Portugal, Brazil, S. 
marcescens in the Netherlands, and P. aeruginosa in South 
Africa [93-97]. The main source of carbapenem resistance in 
A. baumannii is the production of carbapenem-hydrolyzing 
Ambler’s class D -lactamases (CHDL) [98], however GES-
type carbapenemases have been reported for A. baumannii 
[90, 99-101]. Several GES-type -lactamases have been 
identified in A. baumannii: the blaGES-11 gene in France, in 
Kuwait, in Turkey, in Egypt and Palestinian territories, the 
blaGES-12 in Egypt, France and Belgium, and the blaGES-14 
gene in France, in Turkey and in Kuwait [90, 99, 100, 102, 
103] and blaGES-22 in Turkey [104]. 
GES-5 or GES-13 have also been reported worldwide 
now in P. aeruginosa from Korea, China, India, Turkey, 
France, Spain, Mexican and Brazil [14, 105-111]. Thus, 
similar GES variants have now been identified in different 
species from distantly located countries. The blaGES-5 carbap-
enemase gene was found on two plasmids, pRSB113 and 
pRSB115, and inserted within the variable region of two 
different class 1 integrons. These plasmids were recovered 
from an activated sludge of a wastewater treatment plant in 
Germany [112], had different backbones with different in-
compatibility groups, and could replicate both in E. coli and 
in P. aeruginosa. The effluents of wastewater treatment 
plants run into rivers that flow to oceans, likely contaminat-
ing coastal waters with MDR bacteria. The presence of car-
bapenemase-producing enterobacteria was recently evi-
denced in water from touristic beaches located in Rio de Ja-
neiro, Brazil. Predominantly environmental Kluyvera sp or 
Enterobacter sp isolates, producing either KPC-2, GES-5 or 
GES-16 carbapenemases, were evidenced [113]. 
3. GENETICS OF CLASS A CARBAPENEMASES 
The genes for SME-like, IMI-1-like, SFC-1 and NmcA 
are all chromosomally-located, a fact that may have contrib-
uted to their limited spread. None is transmissible and there 
is no evidence of spread, although plasmid-mediated IMI-2 
has been found in clonal environmental E. asburiae isolates 
[34, 53, 58] and in a recent E. coli isolate in Spain [66]. 
Flanking sequences of the imi-R–blaIMI-1 gene complex have 
not been investigated in detail, but it may be part of a com-
posite transposon as it is flanked by different mobile ele-
ments in E. cloacae and E. asburiae [34, 53]. In E. absuriae 
the imi-R–blaIMI-2 region is surrounded by an upstream lo-
cated IS2-like fragment and downstream located transposase 
gene similar to that of Tn2501 [34]. In E. cloacae, the imi-R–
blaIMI-2 genes are flanked on both sides by structures related 
to the transposase gene of Tn903 and further upstream by an 
IS2-like element [34, 53]. These mobile elements may have 
been at the origin of blaIMI gene mobilization, but whether 
they are still active is unknown. Their possible inactivity 
might explain the rare occurrence of blaIMI genes in these 
species. Similarly, the blaFRI-1 gene is plasmid-encoded, and 
associated with a LysR type regulator suggesting a similar 
genetic organization as for IMI-2 enzymes. It is likely that 
FRI-1 is naturally present in an enterobacterial isolate 
(probably environmental) and that it moved through mobile 
elements onto the 150-kb plasmid. There is however no indi-
cation on mobile elements associated with blaFRI-1 gene. Re-
cent whole-genome sequencing results from three Canadian 
isolates revealed that the blaSME gene occurred in a novel 
cryptic prophage genomic island, SmarGI1-1. This genomic 
island can be excised and circularized, which probably con-
tributes to its dissemination amongst S. marcescens [114]. 
Between 2010 and 2012, 30 S. marcescens belonging to 
three widely disseminated pulsotype clusters were predomi-
nant in Canada, though, none was associated with known 
outbreaks suggesting an ongoing spread of this kind of en-
zymes. All three clusters shared 77% similarity, indicating 
that there may be at least some clonality in SME-harbouring 
isolates. 
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The source of blaBIC-1 gene dissemination in urban water 
is probably also linked to mobile genetic elements, two unre-
lated insertion sequences located upstream and downstream 
of the blaBIC-1 gene. The role of these elements in the mobil-
ity of the blaBIC-1 gene has not been investigated [30]. 
The blaGES-1-like and blaKPC genes have been identified 
onto large sized plasmids of different incompatibility groups 
varying in size and structure. In most of the cases, plasmids 
were self-transferable at least to E. coli at high frequency 
(10-2 -10-5). These plasmids may carry in addition other -
lactamase genes, aminoglycoside resistance genes and qnr 
resistance determinants. In most cases the blaGES-1-like genes 
are part of a gene cassette, located in the variable regions of 
class 1 integrons. However, in rare cases they may be em-
bedded in a class 3 integron or present on integron mobiliza-
tion units (IMU), that have similar characteristics to those of 
miniature inverted transposable elements (MITEs) [115]. 
The blaKPC genes are located on a 10-kb Tn3-type trans-
poson, called Tn4401. Tn4401 possesses two unrelated inser-
tion sequences ISKpn7 and ISKpn6, inserted upstream and 
downstream of blaKPC, respectively. Several isoforms of 
Tn4401 (differing by a 100 to 200 bp deletion upstream of 
blaKPC), have been identified in most KPC-producing bacte-
rial isolates all around the world [116]. In a few KPC-
producing enterobacterial isolates other mobile elements 
have been found immediately upstream of blaKPC gene, but 
the downstream-located sequence was identical to Tn4401 
sequences, suggesting that these novel mobile elements have 
inserted into the Tn4401 backbone. Transposition assays 
revealed that Tn4401 is an active transposon capable of mo-
bilizing the carbapenemase blaKPC gene at high frequency 
(2x10-5 per recipient cell), without apparent preferred inser-
tion site, but always with a 5-bp target site duplication [74]. 
The very efficient dissemination of blaKPC-producers world-
wide is likely associated with spread of strains, plasmids and 
transposons. 
The chromosomal NmcA/IMI/SME -lactamases can be 
induced in response to imipenem and cefoxitin, resulting in 
substantial increases of activity against imipenem. Upstream 
of blaNmcA, blaIMI-1, blaFRI-1 and blaSME-1 the presence of a 
divergently transcribed gene related to the LysR family of 
DNA-binding transcriptional regulatory genes was found 
[26, 37, 61]. Deletions of the nmcR gene located upstream of 
blaNmcA eliminated the NmcA inducibility and reduced car-
bapenem MICs, suggesting that NmcR is a positive regulator 
of NmcA expression [37]. The ImiR protein shares 97% 
amino acid sequence identity with NmcR, but an analysis of 
its regulatory effects has not been published. SmeR is 69% 
identical to NmcR but has a weaker positive regulatory activ-
ity on the blaSME-1 gene expression. NmcA carbapenemase 
induction was also found to be linked to AmpD as shown for 
the induction of the chromosomally-encoded cepha-
losporinase AmpC [117]. The blaIMI-1 gene and its regulator 
imi-R gene are embedded in the chromosome of the host, 
whereas the blaIMI-2 genes and their imi-R genes are plasmid-
borne. Constitutive expression of blaSME-1 was shown to im-
part a fitness cost upon E. coli. This SME-1-associated fit-
ness cost may also explain their limited dissemination and 
the inducible nature of these kind of enzymes [45]. KPC-
like, GES-like, SFC-1, BIC-1, PenA and FPH-1 are constitu-
tively expressed. 
4. ORIGIN OF CLASS A CARBAPENEMASES 
Imipenem is an N-formimidoyl derivative of thienamy-
cin, a natural carbapenem compound produced by a soil or-
ganism called Streptomyces cattleya. Bacteria that produce 
carbapenem-hydrolyzing enzymes would be well adapted to 
survive in the soil or more general in the environment. The 
first class A carbapenemase producing isolates, SME-1-
producing S. marcescens in 1982 in London [24, 38] and 
IMI-1- producing E. cloacae isolate in 1984 in the USA [26], 
were identified even before imipenem was released for clini-
cal use in 1985 in USA. This strongly suggested that class A 
carbapenemases of IMI/NmcA, SME, FRI-1, BIC-1, KPC 
and SFC-1 enzymes, which share a common ancestor (Fig. 
2), have existed before the clinical use of imipenem, and are 
not a consequence of imipenem use driving the evolution of 
-lactamases. This situation is likely different with the other 
class A carbapenemases (Fig. 2), which have quite distinct 
ancestors (GES enzymes, PenA, FPH-1 and SHV-38) and 
totally unrelated to each other. For GES-enzymes the use of 
carbapenems may have played a role in the selection of 
GES-carbapenemases, as they are point mutant derivatives of 
GES-1, an ESBL lacking carbapenemase activity. The intrin-
sic carbapenemase activity of all members of the IMI/NmcA, 
SME, FRI-1, BIC-1, KPC and SFC-1 cluster suggests that 
the common ancestor was already capable of carbapenem 
hydrolysis. The serine -lactamases are believed to have 
evolved from the Penicillin Binding Proteins (PBPs: -
lactam target) through changes in the active site, such as 
inclusion of water molecule and other requisites of the hy-
drolytic machinery [11]. In addition, the class A carbapene-
mase genes associated with a LysR regulator gene are those 
most identical to each other, i.e. the blaIMI, blaNmcA, blaFRI 
and blaSME genes, further supporting that they originate from 
a common ancestor (Fig. 2). These genes are, however, far 
from ubiquitous in the species carrying them. 
5. BIOCHEMICAL PROPERTIES OF CLASS A CAR-
BAPENEMASES 
Whereas there is no consensus definition of carbapene-
mases, they have been categorized as enzymes capable of 
hydrolyzing imipenem with kcat/Vmax > 1 M-1S-1 [92, 118]. 
However, this an arbitrary cut-off that does not take into 
account the fact that not all carbapenems are hydrolysed by 
all carbapenemases and that the level of resistance may de-
pend on the genetic background of the host organism [92]. 
Queenan and Bush used the kcat value for distinguishing 
strong hydrolysis (generally, kcat > 2 s1), weak hydrolysis 
(generally, kcat of 0.5 to 2 s1), and no measurable hydrolysis 
reported (generally, kcat of < 0.5 s1) [13]. Using these crite-
ria GES-enzymes, PenA, FPH-1 and SHV-38 would not be 
carbapenemases (Table 3). By far SHV-38 has the worst kcat 
(0.01 s-1), and also the lowest catalytic efficiency (kcat /Km: 
0.0004 M-1.s-1). SHV-38 differs from the broad-spectrum 
penicillinase, SHV-1, by Ala146Val substitution (Ambler 
numbering [18]) owing to a single transition. Among the 
known SHV enzymes (more than 191 variants), only SHV-
38 possesses a Val at position 146. All the other SHV -
lactamases have an Ala residue and none of them has car-
bapenemase activity. SHV-38 does not hydrolyse mero-
penem in measurable amounts, but has a high kcat for ceftaz-
idime (110 s-1) [33]. 
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Table 2. Steady-state kinetic parameters for representative class A carbapenemases
#,§
. 
Substrate kcat (s
-1
) 
 SME-1 NmcA IMI-1 SFC-1 BIC-1 KPC-2 GES-4 FPH-1 PenA SHV-38 
Benzylpenicillin 19 260 36  31 63 130   100 
Cephaloridine 980 2820 2000  170 530 490   40 
Cefoxitin <0.15 5.0 0.3 4.2 1 0.95 85 0.26  – 
Cefotaxime <0.98 286 3.4 8.3 20 17 17 – 142 1 
Ceftazidime <0.07 4.7 0.0068 2.1 – 0.49 2.5 –  110 
Cefepime      12    3 
Aztreonam 108 707 51 162 35 66 – – 60 3 
Imipenem 104 1040 89 54 50 31 0.38 0.15 0.38 0.01 
Meropenem 8.9 12 10 6.5 1 3.6  0.093   
Ertapenem     2   0.11   
 Km (M) 
 SME-1 NmcA IMI-1 SFC-1 BIC-1 KPC-2 GES-4 FPH-1 PenA SHV-38 
Benzylpenicillin 17 28 64  48 30 2200   13 
Cephaloridine 770 185 1070  770 510 160   150 
Cefoxitin ND 93 45 77 825 140 810 120   
Cefotaxime ND 956 190 89 2200 100 700 – 295 800 
Ceftazidime ND 90 270 52 – 230 1500 –  3800 
Cefepime      540 1900   1600 
Aztreonam 260 125 93 484 1000 420 – – 378 5500 
Imipenem 202 92 170 82 300 90 4.7 0,42 7 24 
Meropenem 13 4.4 26 26 12 13  3.1   
Ertapenem     10   1.4   
 kcat/Km (M-1.s-1) 
 SME-1 NmcA IMI-1 SFC-1 BIC-1 KPC-2 GES-4 FPH-1 PenA SHV-38 
Benzylpenicillin 1.1 9.3 0.56  0.65 2.1 0.81   7.7 
Cephaloridine 1.3 15 1.9  0.22 1 0.22   0.27 
Cefoxitin ND 0.053 0.0067 0.054 0.0012 0.0068 0.11 0.0002   
Cefotaxime ND 0.30 0.018 0.093 0.0091 0.17 0.024 – 0.48 0.0013 
Ceftazidime ND 0.052 0.00003 0.04 – 0.0021 0.0017 –  0.029 
Cefepime      0.022 0.6   0.0019 
Aztreonam 0.42 5.7 0.55 0.33 0.0035 0.16 – – 0.16 0.0005 
Imipenem 0.51 11 0.52 0.66 0.17 0.34 0.081 0.36 0.05 0.0004 
Meropenem 0.68 2.7 0.038 0.25 0.08 0.28  0.03   
Ertapenem     0.2   0.079   
# References: SME-1 [24]; NmcA [25]; IMI-1 [26]; KPC-2 [27]; GES-4 [28]; SFC-1 [29]; BIC-1 [30]; FPH-1 [31]; PenA [32]; SHV-38 [33]. 
§ Abbreviations: ND: not determinable; empty cell: no data available; '–': no detectable hydrolysis. 
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Table 3. Substrate and inhibition profiles of the carbapenemases (adapted from reference [13])
#,§
. 
    Hydrolysis Profile Inh  
Enzyme 
Number of 
Variants 
Host Expression Type PEN CEF CEP-I CEP-III AZT CARBA CA Reference 
Chromosome            
NmcA 1 E. cloacae inducible LysR + + + + + + + [25] 
IMI-1-like 8 E. cloacae inducible LysR +  +  + + + [26] 
SME-like 6 S. marcescens inducible LysR +  + ± + + + [24] 
SFC-1 1 S. fonticola constitutive + + +  + +  [29] 
BIC-1 1 P. fluorescens constitutive + ± + ± + +  [30] 
SHV-38 1 K. pneumoniae constitutive +  + + + ± ++ [33] 
FPH-1 1 F. philomiragia constitutive +  + + + + ± [31] 
PenA 1 B. multivorans constitutive +  + + + + ± [32] 
Plasmid            
IMI-2  E. asburiae, E. coli inducible LysR +  +  + + + [34] 
KPC-like 22 
Enterobacteriaceae, 
P. aeruginosa, A. 
baumannii 
constitutive + ± + + + + ± [17, 27] 
GES-like 23 
Enterobacteriaceae, 
P. aeruginosa, A. 
baumannii 
constitutive + ±a + + b ± ± [14] 
FRI-1 1 E. cloacae inducible LysR +  + + + + + [67] 
a + for GES variants displaying a serine in position 170 
b Except for GES variants dispalying a serine or alanine in position 243 
# Symbols: + : strong hydrolysis (generally, kcat of > 2 s1); ± : weak hydrolysis (generally, kcat of 0.5 to 2 s1); '' : no measurable hydrolysis reported (generally, kcat of < 0.5 s1). 
§ Abbreviations: Inh: Inhibition; PEN: Penicillins ; CEF : Cefoxitin ; CEP-I : Early cephalosporins ; CEP-III : Expanded-spectrum cephalosporins ; AZT : Aztreonam ; CARBA : 
Carbapenems ; CA : Clavulanic acid. 
SME, NmcA, and IMI enzymes have a broad spectrum of 
hydrolysis that includes the penicillins, early cephalosporins, 
aztreonam, and carbapenems (Tables 2 and 3). Imipenem 
hydrolysis was easily measurable, with kcat values of >30 s-1 
while that of meropenem was at least 10-fold lower. Ce-
foxitin and expanded-spectrum cephalosporins were ineffi-
ciently hydrolyzed, when hydrolysis could be detected at all, 
and overall cefotaxime was more efficiently hydrolyzed than 
ceftazidime (Tables 2 and 3). SFC-1 and FRI-1 displayed a 
similar hydrolytic profile, e.g. significant hydrolysis of peni-
cillins, aztreonam and carbapenems, but not of expanded-
spectrum cephalosporins [29, 67]. The IC50 of clavulanic acid 
and tazobactam were however 10-fold higher than those 
found for NmcA, IMI and SME, leading to a lower suscepti-
bility towards -lactamase inhibitors [67]. Unlike IMI/NmcA 
and SME types, KPC -lactamases (KPC-1/2 to KPC-23) 
confer decreased susceptibility or resistance to virtually all 
-lactams and are only weakly inhibited by typical class A 
inhibitors (Tables 2, 3 and 4). 
BIC-1 hydrolyzed penicillins, cephalosporins, carbap-
enems, and monobactams. However, BIC-1 showed no de-
tectable activity against ceftazidime and was weakly inhib-
ited by clavulanic acid (IC50, 30 M) and tazobactam (IC50, 
6.5 M). These values are in the same range as for those of 
KPC-2, with 10.5 and 0.37 M for clavulanic acid and ta-
zobactam, respectively (Table 5).  
The GES enzymes possess an unusual phenotypic vari-
ability, similar to that of the TEM and SHV enzymes that 
can extended their spectrum of activity. Indeed, GES-
enzymes may extend their activities against carbapenems, 
expanded-spectrum -lactams, cephamycins and/or mono-
bactams by single amino acid changes as compared to GES-
1. GES-2 was the first example of an ESBL that has ex-
tended its activity against carbapenems and reduced suscep-
tibility to inhibitors, by a single Gly170Asn change inside 
the omega loop of the catalytic site [86]. A Gly170Ser 
change was then identified in GES-4, -5, and -6, resulting in 
slow carbapenem hydrolysis, in weak inhibitor susceptibility 
(as for GES-2), and additionally, in hydrolysis of cephamy-
cin, and increased ceftazidime hydrolysis, as shown for 
GES-4 [119]. GES-9, which differs from GES-1 by a 
Gly243Ser change, does not hydrolyze carbapenems but has 
extended its activity towards monobactams [85]. Among the 
26 assigned GES variants 25 have available sequence (Lahey 
Clinics, http://www.lahey.org/Studies/other.asp#OTHGES), 
two have Gly170Asn (GES-2, GES-13) and 10 Gly170Ser 
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(GES-4,5,6,14,15,16,18,20,21,24) mutations and are likely 
displaying carbapenemase activity (Table 6). One of them, 
GES-14 that has Gly170Ser and Gly243Ser amino acid 
changes, has extended its spectrum towards carbapenems, 
aztreonam and cephamycins and has reduced susceptibility 
towards inhibitors [90]. 
 
Table 4. IC50 values of class A carbapenemases. 
Inhibition IC50 (M) 
Enzyme 
Clavulanic 
Acid 
Tazobactam Sulbactam 
Reference 
NmcA 1.61 0.66 5.9 [25] 
IMI-1 0.28 0.03 1.8 [26] 
SME-1 0.28 0.16  [24] 
SFC-1 72.8 6.9 22.7 [29] 
BIC-1 30 6.5  [30] 
SHV-38 0.045 0.17 5 [33] 
FPH-1 7.5 4 220 [31] 
PenA 3.1 0.5 4.1 [32] 
KPC-2 10.5 0.374  [17, 35] 
GES-4 15 1.4 15 [14] 
 
PenA and FPH-1 enzymes have low kcat values for 
imipenem (comparable to those of GES-carbapenemase-type 
enzymes). However PenA hydrolyzes cefotaxime with a 
higher kcat value and both are moderately inhibited by -
lactamase inhibitors. 
6. STRUCTURE-FUNCTION RELATIONSHIP 
6.1. Structural Features 
6.1.1. General Overview 
Class A carbapenemases are monomeric enzymes con-
taining 265 to 269 amino acid residues, and with molecular 
weights from 25 to 32 kDa. The hydrolysis mechanism of 
class A carbapenemase is similar to other active-site serine 
-lactamases, proceeding via a three-step mechanism involv-
ing formation of the non-covalent Michaelis complex, acyla-
tion and deacylation (Fig. 1). 
Class A carbapenemases present the same four conserved 
motifs that are characteristic to the class A serine -
lactamases (Fig. 3). The first motif is 70SXXK73 (ABL num-
bering scheme [18]), where X represents a variable residue, 
Ser70 is the active-site serine and Lys73 is the lysine residue 
situated in the immediate proximity which was shown to 
promote Ser70 addition to the -lactam carbonyl [120]. The 
second element, 130SDN132, is equivalent to the conserved 
motifs YA/SN and SXV/I from class C and class D -
lactamases, respectively. The third one is represented by 
Glu166, which acts as a general base for the deacylation of 
the acyl-enzyme complex, being part of a more general 
166EXXXN170 motif that is generally found in the omega 
loop. Finally, the 234KTG236 motif is common to most serine-
active -lactamases. 
Cystein residues 69C and 238C form a disulfide bond in the 
majority of class A carbapenemase (a notable exception be-
ing PenA). As this structural feature is not present in other 
class A -lactamases it was thought to be directly related to 
the carbapenem-hydrolyzing activity of these enzymes. It 
was later shown, with SME-1 as example, that this disulfide 
bond does not uniquely influence the carbapenemase activity 
of -lactamases but is required in general for the enzyme to 
function as a -lactamase [121]. Other class A -lactamases 
(i.e. GES-1) possess cysteines at positions 69 and 238 with-
out having significant carbapenemase activities, acting as 
extended-spectrum cephalosporinases instead [121]. How-
ever, these enzymes may become true carbapenemases by 
single amino-acid changes at position 170. 
A number of 22 crystal structures are currently available 
in the Protein Data Bank (PDB) [122] (Table 7). The super-
position of all these structures (Fig. 4) shows that they share 
the same fold, with very well conserved structural features. 
There are, however, 5 regions (A-E) presenting significant 
differences in the backbone conformation. These regions, 
which are situated relatively far from the active site and 
more likely do not influence directly the activity and the se-
lectivity of class A carbapenemases, will be analyzed in 
more detail below (see Fig. 4 for more details): 
(i) Region A (positions 49 to 57) can be divided in two 
groups of structures: those corresponding to the GES struc-
tures on one hand, and all the other structures on the other. 
This difference of conformation might be explained by the 
presence of a Pro51 in all GES structures, whereas the others 
present a conserved threonine at this position. On this basis 
we can predict that FRI-1, which also has a proline at the 
position 51, will adopt a conformation similar to GES in this 
region; 
(ii) in the region B (positions 87 to 90), SFC-1, KPC-2 and 
PenA present one conformation, whereas GES, NmcA and 
SME-1 adopt a different shape. The presence of a glycine 
residue at the position 89 in the first group of enzymes and 
its absence in the second group probably explains this differ-
ence in the backbone conformation; 
(iii) region C is situated between positions 97 and 103. 
KPC-2, PenA and GES form a group with a characteristic 
conformation, whereas NmcA, SFC-1 and SME-1 adopt an-
other conformation. The residue responsible for this confor-
mational change is probably the glycine at the position 98, 
which is present in the first group, but not in the second; 
(iv) the fourth region, D (positions 195 to 197), present a 
different conformation for the GES structures compared to 
all others. This is probably due to the presence of a glycine 
residue at the position 197 in the GES structures, which is 
not present in the others; 
(v) region E (positions 265 to 276) shows again a different 
conformation for the GES structures compared to all others. 
Although it is tempting, on the basis of the sequence 
1016    Current Drug Targets, 2016, Vol. 17, No. 9 Naas et al. 
Table 5. Sequence alignment for the KPC family.
a,b
 Only the positions with mutations or deletions are shown. 
Position
c
 49 92 104 105 120 147 169 202 207 240 242 243 274 286 
KPC-2 M D P W A G L P F V G T H N 
KPC-3             Y  
KPC-4   R       G     
KPC-5   R            
KPC-6          G     
KPC-7 I            Y  
KPC-8          G   Y  
KPC-9          A   Y  
KPC-10   R          Y  
KPC-11   L            
KPC-12       M        
KPC-13  G           Y  
KPC-14           –d –d   
KPC-15   R  L K    G   Y  
KPC-16        S L      
KPC-17         L      
KPC-18a •a • • • • • • • • • • • • • 
KPC-19             Y T 
KPC-20a •a • • • • • • • • • • • • • 
KPC-21    R           
KPC-22    G     L      
KPC-23a •a • • • • • • • • • • • • • 
a The sequences for KPC-18, KPC-20 and KPC-23 are not currently available ; b Sequences of KPC-1 and KPC-2 are identical [36] ; c ABL numbering scheme [18] ; d Deletions 
 
Table 6. Sequence alignment for the GES family.
a
 Only the positions with mutations or deletions are shown. 
Position
b
 15 16 43 56 62 80 81 104 125 130 167 169 170 237 243 
GES-1# G I Q I M V F E A S P M G T G 
GES-2*             N   
GES-3#     T   K        
GES-4*     T   K     S   
GES-5*             S   
GES-6*        K     S   
GES-7#        K        
GES-8#         L       
GES-9#               S 
GES-10#  T   T     C      
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(Table 6) contd…. 
Position
b
 15 16 43 56 62 80 81 104 125 130 167 169 170 237 243 
GES-11#               A 
GES-12#              A A 
GES-13#        K     N   
GES-14*             S  A 
GES-15           S  S   
GES-16   E          S   
GES-17        K       A 
GES-18*      I       S   
GES-19# A              A 
GES-20* A            S   
GES-21       L      S   
GES-22#            L   A 
GES-23    L            
GES-24     T        S   
GES-25a •a • • • • • • • • • • • • • • 
GES-26 A               
a The sequence of GES-25 is not currently available 
b ABL numbering scheme [18]. 
# Extended-spectrum -lactamase (ESBL) 
* Carbapenemase 
alignment, to suggest that the lysine residue present in posi-
tion 273 in all structures except GES is responsible for this 
conformational differentiation, a more in depth analysis of 
three-dimensional structures shows that this Lys273 is not 
involved in any stabilizing interaction with neighbouring 
residues. A more pertinent explanation would be the pres-
ence in GES, but not in the other structures, of Ser271 and 
Glu274 residues that are stabilizing the helix structure in this 
region, and of Arg275 that is involved in longer distance 
stabilizing interactions with the backbone of Ala266 and 
Pro267. 
Although a comparison of the active sites of carbapenem-
hydrolyzing and carbapenem-inhibited class A -lactamases 
does not reveal important structural differences [123, 124], it 
was reported that a close analysis of the active sites of car-
bapenem-hydrolyzing (SFC-1, KPC-2, NmcA, SME-1) in 
comparison with those of carbapenem-inhibited (TEM-1, 
SHV-1, CTX-M, BlaC) class A -lactamases can reveal dif-
ferences in the positions of the conserved amino acids 
(Ser70, Lys73, Ser130-Asn132, Glu166, Lys234-Gly236) 
that are characteristic for each group of enzymes (Fig. 5) 
[60]. However, when this comparison is conducted with a 
more important number of class A -lactamases with (KPC-
2, GES-2, GES-5, GES-18, NmcA, SFC-1, SME-1, PenA) 
and without carbapenem-hydrolyzing activity (SHV-2, 
TEM-1, CTX-M-9, BEL-1, GES-1, PenI, BlaC, BS3), the 
two groups cannot be discriminated anymore using the posi-
tion of the above-mentioned amino acids (Fig. 5). Nonethe-
less, the carbapenemase activity can be predicted qualita-
tively with good confidence through QM/MM dynamics 
simulations of acyl-enzyme deacylation, requiring only the 
3D structure of the apo-enzyme [125]. 
6.1.2. KPC-2 Structures 
A number of 7 crystal structures of KPC-2 have been de-
scribed to date (Table 7) [123, 126-128]. The first structure 
(PDB 2OV5), released in 2007, has a bicine buffer molecule 
in the active site that interacts via its carboxyl group with 
conserved active site residues Ser130, Lys234, Thr235, and 
Thr237. The formed interactions are similar to those made 
by the -lactam carboxyl moiety in the Michaelis-Menten 
complex. This structure evidence shifts in the position of 
residues Ser70, Asn132 and Asn170, potentially allowing an 
easier access of bulky substrates [123]. In absence of ligand 
in the active site, KPC-2 crystallizes as a dimer (PDB 
3DW0), with the binding site of a monomer occupied by the 
C-terminal residues coming from the symmetric KPC-2 
monomer. This mode of binding is somewhat similar with 
the interaction between -lactamases and the inhibitory pro-
tein BLIP. Deletion of the five C-terminal residues of KPC-2 
results in a monomeric structure (PDB 3C5A), and in a cit-
rate molecule bound to the active site [126]. The interactions 
between KPC-2 and BLIP have been evidenced in two struc-
tures (PDB 3E2K and 3E2L), thus providing a structural 
justification for the sub-nanomolar affinity evidenced ex-
perimentally for this interaction. The conformational flexibil-
ity of the F142 loop of BLIP as observed in these structures 
seems to contribute to BLIP’s promiscuity, enabling it to
1018    Current Drug Targets, 2016, Vol. 17, No. 9 Naas et al. 
 
Fig. (3). Sequence alignment of representative class A carbapenemases. The stars highlight the four conserved motifs that are characteristic of 
class A -lactamases: 70SXX73K, 130SD132N, 166E and 234KT236G (ABL numbering scheme [18]). The triangles indicate the positions of cystein 
residues involved in the 69S238S disulfide bond. The image was generated with ESPript [23]. 
respond to mutations at the -lactamase interface [127]. 
Both structures used in this study possess a Gly175Ser 
mutation that was reported as KPC-1 initially [35, 36]. 
However, Gly175Ser mutation is not located in the BLIP 
interface, nor does it alter the binding affinity, and there-
fore the results can be extrapolated for the wild-type 
KPC-2 [127]. The first structures of KPC-2 with ligands 
trapped as acyl-enzyme complexes (PDB 3RXW and 
3RXX) were recently reported [128]. In the first structure, 
the 3-nitrophenyl boronic acid ligand is covalently-bound 
to Ser70, the two boron hydroxyl groups are positioned in 
the deacylation water pocket and in the oxyanion hole, 
and the aromatic ring of the ligand provides an edge-to-
face interaction with the active site Trp105. The co-
crystalization of KPC-2 with PSR-3-226, a penam sul-
fone, shows a trans-enamine intermediate covalently-
bound to Ser70, with the carbonyl oxygen positioned in 
the oxyanion hole and the carboxyl moiety interacting 
with the active site residues: Asn132, Asn170 and Glu166 
[128]. 
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Fig. (4). Superposition of all three-dimensional structures of class A 
carbapenemases available in the PDB (see Table 7 for the correspond-
ing PDB codes): KPC-2 in blue (7), GES-2 in red (3), GES-5 in orange 
(2), GES-18 in yellow (1), NmcA in green (2), SFC-1 in cyan (3), 
SME-1 in magenta (1), PenA in gray (1). The image was generated 
using Chimera [137]. 
6.1.3. GES-type Structures 
X-ray structures for the GES-2 enzyme in native form 
(PDB 3NI9) [129] and in complex with the ligands tazobac-
tam (PDB 3NIA) [129] and ertapenem (PDB 4QU3) [130] 
have been obtained, showing a good similarity of the three-
dimensional structures (r.m.s. deviations between 1.1 and 1.4 
Å) compared with other class A penicillinases and carbap-
enemases (e.g. GES-1, NmcA, SME-1, KPC-2, TEM-1, 
SHV-1) [129]. The structure of tazobactam bound to 70Ser is 
compatible with either the trans-enamine or imine interme-
diates [129], whereas the acyl-enzyme complex with ertap-
enem clearly shows a pre-isomerized form of the ligand, 
with the pyrroline ring adopting the 2 tautomeric form, the 
C2 atom sp2 hybridized and the S21 sulfur coplanar with the 
pyrroline ring. The core of ertapenem, comprising the pyr-
roline, carboxylate and hydroxyethyl moieties, is anchored 
by a total of eight hydrogen bonds to the surrounding protein 
molecule, whereas the tail of the molecule, comprising the
 
Fig. (5). Three-dimensional structures of active site residues of class A -lactamases with and without carbapenem-hydrolyzing activity, 
colored in green and orange, respectively (see the main text for details). 
 
 
Fig. (6). Superposition of X-ray structures of KPC-2 (apo form, blue, PDB 2OV5) and CTX-M-15 (complex with avibactam, orange, PDB 
4S2I). 
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Table 7. Crystal structures of class A carbapenemases available in the PDB. 
PDB Code Class A Carbapenemase Ligand Mutation Reference 
2OV5 KPC-2 – – [123] 
3C5A KPC-2 – – [126] 
3DW0 KPC-2 – – [126] 
3E2K KPC-2 – G175S [127] 
3E2L KPC-2 – G175S [127] 
3RXW KPC-2 penam sulfone PSR-3-226 – [128] 
3RXX KPC-2 3-nitrophenyl boronic acid – [128] 
3NI9 GES-2 – – [129] 
3NIA GES-2 tazobactam intermediate – [129] 
4QU3 GES-2 ertapenem, pre-isomerized – [130] 
4GNU GES-5 – – [131] 
4H8R GES-5 imipenem, open form – [131] 
3V3S GES-18 – – [132] 
1BUE NmcA – – [133] 
1BUL NmcA penicillanic acid derivative, open form – [134] 
4EQI SFC-1 – – [60] 
4EUZ SFC-1 meropenem, closed form* S70A [60] 
4EV4 SFC-1 meropenem, bound form E166A [60] 
1DY6 SME-1 – – [135] 
3W4Q PenA – – [65] 
* Non-covalent, Michaelis complex. All other ligands mentioned in the table are covalently bound. 
pyrrolidine and carboxyphenyl rings, makes no direct con-
tacts with the protein [130]. Together with UV spectrometry 
and mass spectroscopy experiments, these crystallographic 
studies show that inhibition by tazobactam is not manifested 
through irreversible inactivation, but via the accumulation of 
multiple stable intermediates [129]. 
Two crystal structures were reported for the GES-5 car-
bapenemase, one in the apo form (PDB 4GNU) and one in 
complex with the open form of imipenem, which is cova-
lently-bound to Ser70 (PDB 4H8R). The two structures are 
very similar, but with a significant difference: the presence 
in the GES-5imipenem complex of a water molecule that 
cannot be observed in the apo structure, and occupying a site 
similar to that assigned to the deacylating water molecule in 
GES-1 [136]. This water molecule interacts through hydro-
gen bonds with Ser70 and Glu166, which are also connected 
by a hydrogen bond. Molecular dynamics simulations 
showed that this latter interaction is very stable in GES-5 as 
compared to TEM-1, thus allowing the Glu166 side chain to 
remain in the right position to interact with the hydrolytic 
water molecule and thus to promote efficient deacylation 
step [136]. 
Similarly, the X-ray structure of GES-18 (PDB 3V3S), 
obtained in the apo form, was found to be very close to that 
of GES-11 [132]. The substitution of Gly170Ser leads to the 
formation of additional hydrogen bonds between the Ser70 
and the Glu166 residues with the hydrolytic water molecule, 
which is in agreement with the hydrolysis mechanism pro-
posed for GES-5 (see above). Interestingly, both Gly170Ser 
and Gly243Ala mutations (as compared with GES-1) have 
identical effects on aztreonam and ceftazidime hydrolysis 
(decreased or increased, respectively). This peculiarity may be 
explained by the similarity between the structures of these 
two antibiotics that have the same (C3/C7) side chain, al-
though attached to a different nucleus [132]. 
6.1.4. NmcA Structures 
Two crystal structures have been described for the 
NmcA carbapenemase, both in 1998, one of them being in 
the apo form (PDB 1BUE) [133] and the other in complex 
with the open form of a penicillanic acid derivative cova-
lently-bound to Ser70 (PDB 1BUL) [134]. In the latter, the 
ester carbonyl of the ligand that is located within the 
oxyanion hole, makes hydrogen bonds with the backbone 
nitrogens of Ser237 and Ser70 residues. The repositioning 
of helix H5 away from the active site allows the hydroxyl 
Structural and functional aspects of class A carbapenemases Current Drug Targets, 2016, Vol. 17, No. 9    1021 
group of the 6R-hydroxypropyl moiety to be at hydrogen-
bonding distance to Lys73 N, to Asn132 (bifurcated hy-
drogen bond to O1 and to N2), and to the hydrolytic wa-
ter. The steric crowding provided by the two geminal 
methyl groups protects the ester carbonyl from the attack of 
the hydrolytic water molecule [134]. The overall structures 
are close to those of other class A enzymes. However, the 
two domains are in a slightly different orientation, which 
results in substrate binding and folding variations in the 
helical domain of the protein that affect the position of he-
lix H5. The hydrolytic water molecule, coordinated by 
Glu166 and Asn170 residues, is in the same position as in 
the TEM-1 enzyme. However, Asn132 residue is further 
away from the active site, thus providing additional space 
in this region of the protein for the accommodation of 
poorer substrates of class A -lactamases (cephamycins and 
carbapenems). 
6.1.5. SFC-1 Structures 
Crystal structures of SFC-1 (PDB 4EQI) and of com-
plexes of its Ser70Ala (non-covalent Michaelis complex) and 
Glu166Ala (acyl-enzyme complex) mutants with meropenem 
(PDB 4EUZ and 4EV4, respectively) have been obtained 
[60]. As expected, the acylation-deficient Ser70Ala mutant 
binds meropenem in the unhydrolyzed form, with a well-
defined orientation in which the complete molecule is clearly 
resolved. Meropenem is in the open form in the acyl-enzyme 
complex, and bound covalently to Ser70, allowing the 6-
1R-hydroxyethyl group to interact with Asn132, but not with 
the deacylating water molecule. Comparison of these struc-
tures with those of class A -lactamases inhibited by carbap-
enems revealed that subtle repositioning of key residues in 
SFC-1 (Ser70, Ser130, Asn132 and Asn170) enlarges the 
active site, this allowing rotation of the carbapenem 6-1R-
hydroxyethyl group and thus preventing the deacylating wa-
ter molecule to interact. These results suggest that SFC-1, 
and most likely other class A carbapenemases, needs Asn132 
to orient the bound carbapenems for efficient deacylation 
and prevent their interaction with the deacylating water 
molecule [60]. 
6.1.6. SME-1 Structure 
The overall structure of SME-1 carbapenemase (PDB 
1DY6) [135] is superimposable to that of other class A -
lactamases. Active site residues are also conserved, with the 
exception of positions 104, 105 and 237. In addition, SME-1 
has a shorter (1.4 Å) distance between Ser70 and Glu166 
side chains, as compared with other class A -lactamases. 
This direct hydrogen-bonding interaction between the side 
chains of Ser70 and Glu166 in SME-1 may strongly enhance 
the nucleophilicity of the hydroxyl group of the Ser70 resi-
due for the initial attack on the carbonyl C atom of the -
lactam ring of imipenem [135]. Additionally, as the SME-1 
active site cannot accommodate the water molecule that is 
essential for catalytic activity and normally present between 
Ser70 and Glu166 in the other class A -lactamases de-
scribed, SME-1 may undergo significant conformational 
changes to position properly the water molecule responsible 
for the hydrolysis of acyl-enzyme intermediate [135]. 
6.1.7. PenA Structure 
The X-ray crystal structure of PenA, a -lactamase iso-
lated from B. cepacia possesing carbapenemase activity, has 
been recently obtained (PDB 3W4Q) [65]. This structure 
reveals important differences that aid in understanding the 
contrasting phenotype of PenA compared to PenI, a -
lactamase isolated from B. pseudomallei that has 62% se-
quence identity with PenA and has an extended-spectrum 
hydrolytic profile. These differences include changes in the 
positioning of conserved catalytic residues (Lys73, Ser130, 
Tyr105), as well as altered anchoring and decreased occu-
pancy of the deacylation water. On the other hand, it is 
noteworthy the lack in PenA of a disulfide bond that is pre-
sent between Cys69 and Cys238 in KPC-2 as well as other 
class A carbapenemases, while conserving the carbapenem-
hydrolyzing activity. However, PenA is similar to KPC-2 in 
the five major motifs shared by the class A carbapenemases : 
(i) 70SXXK73 motif ; (ii) 130SDN132 loop ; (iii) 234KTG236 mo-
tif and B3 -strand ; (iv) 102-110 loop and (v)  loop and 
deacylation water. These similarities between their pheno-
types may explain the carbapenemase activity of PenA [65].  
6.2. Site-Directed Mutagenesis Investigations 
6.2.1. KPC-2 
Site-saturation mutagenesis was used to explore the role 
of residue Trp105 in KPC-2. Four variants (Trp105Phe, 
Trp105Asn, Trp105Leu and Trp105Val) were studied in 
more depth. The Trp105Asn mutant showed increased Kms 
for all tested substrates. In contrast, the Trp105Leu and 
Trp105Val mutants displayed decreased catalytic efficiencies 
(kcat/Km) for all substrates. All the three mutants displayed 
increased Kis and partition ratios for clavulanic acid. Overall, 
these data demonstrate that the Trp105 residue in KPC-2 is 
essential for the hydrolysis of substrates [138]. 
Site-directed mutagenesis at the position R220 of KPC-2 
was found to influence selectively the catalytic activity to-
ward substrates, since more than 50% reduction in kcat/Km is 
observed in mutants of the amino acid. In addition, the R220 
seems to play a central role in -lactamase inhibi-
tion/inactivation. Thus, the R220K mutant was relatively 
“inhibitor susceptible”, being not capable anymore to hydro-
lyze clavulanic acid as compared to KPC-2. On the other 
hand, the R220M mutant demonstrated increased Km values 
for -lactamase inhibitors, which resulted in inhibitor resis-
tance [139]. 
Mutagenesis of residue Glu276 into Ala, Asp, Asn and 
Arg revealed that, in contrast to what is observed for other 
class A -lactamases (i.e. TEM-1 and SHV-1), Glu276 has a 
structural role rather than a kinetic function with substrates 
or inhibitors, being anchored to a stabilized water molecule, 
and thus leading to secondary ring opening and protonation 
of the oxonium ion intermediate to form the imine [139]. 
The substitution of the Arg164 residue from the  loop 
of KPC-2 led to enhanced ceftazidime hydrolysis in 11 out 
of 19 variants. The Arg164Ser mutant that was further char-
acterized revealed only a 25% increase in kcat/Km for ceftaz-
idime. Mass spectrometry and pre-steady-state kinetic ex-
periments showed that the rate-limiting step for ceftazidime 
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hydrolysis by KPC-2 was the acylation, while the rate-
limiting step for the Arg164Ser variant was the deacylation, 
thus leading at steady-state to the accumulation of acyl-
enzyme forms. Ceftazidime resistance may thus proceed by a 
novel mechanism that uses “covalent trapping” of the sub-
strate by an enzyme with a lower Km that is impaired in dea-
cylation [140]. 
In a recent study, the efficacy of ampicillin-avibactam 
and ceftazidime-avibactam combinations was tested against 
in vitro generated KPC-2 variants having single amino acid 
changes at key positions (i.e., Ambler positions 69, 130, 234, 
220 and 276 - (see Fig. 6) for a representation of the KPC-2 
binding site superposed to the CTX-M-15 complex with avi-
bactam [141]). KPC-2 with substitutions of Ser130Gly, 
Lys234Arg, and Arg220Met showed increased MICs only 
for the ampicillin-avibactam combination and steady-state 
kinetics showed that the Ser130Gly variant was resistant to 
avibactam inactivation. A possible explanation of this result 
could be that the protonation of the sulfate nitrogen of avi-
bactam may be slowed in the Ser130Gly variant as the 
Ser130, which is the likely proton donor, when replaced by 
Gly cannot fulfill this function anymore, suggesting that this 
activity could likely be compensated by Lys234 in the 
Ser130Gly mutant. This mutational analysis revealed the 
major contribution of Ser130, but also Lys234 and Arg220, 
to the mechanism of KPC-2 inhibition by avibactam. Of 
note, emergence in clinic of these KPC variants may not 
result in treatment failures using ceftazidime-avibactam as 
the ceftazidime partner remains a potent antibiotic against 
the E. coli isolates expressing Ser130Gly, Lys234Arg, and 
Arg220Met [142]. 
6.2.2. GES 
In GES-type -lactamases, the residues at position 104 
and 170 are either Glu/Lys and Gly/Asn/Ser, respectively. 
These two positions have been suggested to be key amino 
acids for the interaction with -lactams. Using site-directed 
mutagenesis, the following mutants Glu104/Gly170 (GES-
1), Glu104/Asn170 (GES-2), Glu104/Ser170 (GES-5), 
Lys104/ Ser170 (GES-6), Lys104/Gly170 (GES-7) and 
Lys104/ Asn170 (GES-13) were constructed and their kinetic 
parameters determined in order to elucidate the precise role 
of each position. The Glu104Lys-variant enzymes revealed 
increased oxyimino-cephalosporin and reduced imipenem 
hydrolysis. The Gly170Asn-containing enzymes displayed 
reduced rates of penicillin and cephalosporin hydrolysis, 
whereas the Gly170Ser allowed in addition an increased hy-
drolysis of cefoxitin, and both Gly170Asn and Gly170Ser 
had increased carbapenem-hydrolyzing activity with reduced 
ceftazidime hydrolyzing activity [143]. Similarly, another 
study showed that Gly170Asn led to stable complexes, such 
as a cross-linked species and a hydrated aldehyde [144]. In 
contrast, Gly170Ser led to the formation of a long-lived 
trans-enamine species. The residue at position 170 was also 
pointed out as crucial in the clavulanic acid susceptibility of 
GES enzymes [144]. Pre-steady-state and steady-state kinet-
ics using carbapenems as substrates showed that acylation 
step was rate-limiting for GES-1 (Gly170), whereas the acy-
lation step was enhanced in GES-2 (Asn170), as compared to 
GES-1, thus resulting in acylation /deacylation steps being of 
similar order of magnitude. For GES-5 (Ser170) the acyla-
tion rate increased by 5000-fold and the acylation of the en-
zyme was no longer rate-limiting [145]. 
6.2.3. NmcA 
Site directed mutagenesis was used to investigate the im-
portance of the Cys69 and Cys238 disulfide bridge. These 
cysteine residues represent a major difference between class 
A carbapenemases and non-carbapenemases. By replacing 
them by alanines, it was observed that the removal of the 
disulfide bridge in the NmcA active site yielded a highly 
unstable enzyme, which could not be produced and purified 
to homogeneity [146]. 
The substitution of Asn132 in NmcA with alanine or glu-
tamine (Asn132Ala and Asn132Gln mutants) led to the se-
vere impairment of the catalytic efficiency (e.g. kcat/Km de-
creased more than 103 fold for ampicillin). A similar behav-
iour, strong decrease of the -lactamase activity, has been 
observed in the case of the same TEM-1 mutants. These re-
sults indicated that Asn132 is an important residue in the 
catalytic activity of class A -lactamases, but not typical for 
the carbapenamase activity [146]. 
Mutations at positions 141 (Arg141Ala) and 240 
(Ala240Val, Ala240Glu) did not affect the NmcA activity 
profile, whereas substitution of residue 105 (His105Ser) af-
fected the activity profile of NmcA, the mutant being unable 
to hydrolyse second and third generation cephalosporins, and 
cephamycins. The catalytic activity against carbapenems was 
retained, but the specificity was modified. Unlike the wild 
type enzyme that has a stronger hydrolytic activity against 
imipenem as compared to meropenem, the mutant enzyme 
displayed a catalytic efficiency for meropenem (kcat/Km  106 
M-1.s-1) 10-fold higher as compared to imipenem (kcat/Km  
105 M-1.s-1) [146]. 
6.2.4. SME-1 
Ser237Ala mutant of the carbapenemase SME-1 revealed 
hydrolysis of penicillins and aztreonam in a very similar 
manner to that of SME-1. However, Ser237Ala mutant dis-
played reduced catalytic efficiency against cephems (cepha-
lothin and cephaloridine) and cephamycin (cefoxitin), that 
was almost not detectable with the mutant enzyme. Finally, 
the Ser237Ala mutant presented a decreased catalytic activ-
ity against imipenem, indicating that this serine residue is 
important for the carbapenemase activity of SME-1 [147]. 
The role of the disulfide bridge between Cys69 and 
Cys238 in the hydrolysis of carbapenems and any -lactams 
has also been demonstrated for SME-1. The Cys69Ala mu-
tant enzyme in SME-1 resulted in loss of hydrolysis of all 
the -lactams tested (amoxicillin, ticarcillin, kanamycin, 
cefoxitin, imipenem and aztreonam) [135]. In another study, 
random replacement libraries for these Cys69 and Cys238 
positions were created using PCR-based mutagenesis. Only 
enzymes from these libraries with Cys69 and Cys238 were 
functional and capable to confer resistance to -lactams, 
suggesting that these cysteines and the resulting disulfide 
bridge are detrimental for the hydrolysis of all -lactam anti-
biotics hydrolyzed by SME-1 [121]. 
Similarly, randomized site-directed mutagenesis of SME-
1 residues 104, 105, 132, 167, 237, and 241 was undertaken 
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and functional mutants were selected for their ability to hy-
drolyze imipenem, ampicillin, and cefotaxime. No single 
position contributed alone to carbapenem-hydrolysis, al-
though several positions seemed to be important for -lactam 
antibiotic hydrolysis in general. These results suggest that 
SME-1 carbapenemase activity is due to a highly distributed 
set of interactions that subtly alter the structure of the active-
site pocket [124]. 
6.2.5. SFC-1 
The only SFC-1 mutants generated were acylation 
(Ser70Ala) and deacylation (Glu166Ala) deficient mutants 
that were used to facilitate the trapping of complexes with -
lactams [60]. 
6.2.6. PenA 
In a study aimed at identifying the factors responsible for 
the resistance to ceftazidime in clinical isolates, the effects of 
point mutations, blaPenA gene deletion, and up-regulation 
were investigated. Deletion of blaPenA gene lowered MICs by 
at least 4-fold for 6 of the 9 -lactams tested and by 16-fold 
for ampicillin, amoxicillin, and carbenicillin. Overexpression 
of PenA resulted for all -lactams tested in an increase of 
MICs by 2- to 10-fold. The Cys69Tyr and Pro167Ser mu-
tants of PenA, which were previously observed in resistant 
clinical isolates, increased MICs for ceftazidime by 85- and 
5- to 8-fold, respectively. Similarly, the Ser72Phe amino acid 
substitution resulted in a 4-fold increase in MICs for amox-
icillin and clavulanic acid [148]. 
The sequencing of blaPenA gene in ceftazidime-resistant 
B. thailandensis isolates identified 516 isolates containing a 
single point mutation in the coding region of blaPenA gene. A 
total of 12 amino acid positions were repeatedly found sub-
stituted in these mutants (Ambler positions 69, 136, 162, 
164, 166, 169, 170, 171, 172, 174, 176, 179), ten of them 
being located in the  loop. All mutations show distinct sub-
stitution patterns, distinct MIC levels and different frequen-
cies of occurrence [149]. 
The Glu168 deletion mutant of class A -lactamase 
PenA was able to extend its spectrum of substrates to include 
ceftazidime. This deletion, that was situated in the  loop, 
allowed increased flexibility at the active site by expanding 
the space available in the loop [150]. Similarly, three single-
amino-acid deletions (Thr171, Ile173, and Pro174) and a 
two-amino-acid deletion (Arg165_Thr167_insP i.e. a three-
amino-acid deletion and a proline residue insertion), all of 
them occurring in the  loop, increased the flexibility of the 
binding cavity and extended the substrate spectrum of the 
PenA -lactamase [151]. 
The substitution of Arg220 to Gly in the B. cepacia PenA 
-lactamase resulted in a loss of imipenem resistance and a 
significant decrease in catalytic activity when measured en-
zymatically. These results show that the Arg220 residue is 
critical for the interaction with imipenem [65] and corrobo-
rate well with previous studies reporting that the equivalent 
residue in TEM-1 (Arg224) is able to coordinate a water 
molecule that is the source of the proton required for carbap-
enem tautomerization [152]. 
CONCLUSION 
The -lactamases are ancient enzymes that were relatively 
rare in clinical isolates until -lactam antibiotics were intro-
duced into medicine and agriculture more that sixty years ago 
[153]. -lactamases are the most widespread and important an-
tibiotic resistance determinants in human medicine. The wide-
spread use of all types of -lactam molecules, including the 
broad-spectrum -lactams, cephalosporins and carbapenems, in 
the last three decades has led to the selection of novel -
lactamases with ever broadened spectrum of hydrolysis. Class A 
carbapenemases capable of hydrolyzing most if not all -lactam 
molecules are currently spreading in many gram-negative iso-
lates, best exemplified with the plasmid located enzymes, such 
as KPC and in a lesser extend GES-enzymes. The spread of the 
KPCs in isolates is one of the most frightening issues since it is 
likely that it may become rapidly uncontrollable due to its ap-
pearance in community-acquired pathogens worldwide.  
The number of class A -lactamases displaying carbapene-
mase activity is still limited and the occurrence of most class A 
carbapenemases (besides KPC and to a lesser extend GES) is 
still rare. The most widely dispersed enzymes, KPC enzymes, 
are encoded by genes located on transferable elements inserted 
on different broad-host range plasmids facilitating their dis-
semination, as revealed by the geographical distribution of the 
KPC enzymes. The KPC carbapenemases initially identified in 
K. pneumoniae from the Northeastern parts of USA, is now 
increasingly isolated worlwide. In the light of the global and 
rapid spread of CTX-M enzymes it is conceivable that a similar 
scenario may occur for KPC carbapenemases. Carbapenems are 
drugs resisting hydrolysis by most -lactamases, including 
ESBLs and derepressed chromosomal AmpC -lactamases. 
Thus with the increased dissemination of ESBLs, increased use 
of carbapenems is to be expected in order to treat severe infec-
tions caused by multidrug-resistant pathogens. This will in turn 
facilitate the emergence of carbapenemase producers, especially 
class A -lactamases that can extend their spectrum of activity 
towards carbapenems (GES) or with those possessing already a 
strong carbapenem-hydrolyzing activity (KPC). A wider dis-
semination of the GES and KPC carbapenemases would there-
fore pose major therapeutic issues as the treatment options may 
be seriously limited, possibly with fatal consequences. 
The three-dimensional structures of class A carbapenemases 
share the same fold, with very well conserved structural fea-
tures. There is no distinctive element that can discriminate 
the class A carbapenemases from the non-carbapenemases, 
this difference in phenotypes being the result of multiple 
small changes in the structure, but also in the dynamics of 
the active site residues and in the positioning of water mole-
cules. An exception to this rule is maybe the Cys69-Cys238 
disulfide bond, which is present in the vast majority of class 
A carbapenemases and absent in almost all non-
carbapenemases. As every exception has its own exceptions, 
PenA is a carbapenemase even though this disulfide bond is 
absent (but the carbapenem hydrolysis is weak in PenA 
compared with KPC-2, and this might be possibly related to 
the absence of the disulfide bond), and on the other hand this 
Cys69-Cys238 disulfide bond is conserved throughout the 
GES family, whereas only a few GES enzymes possess car-
bapenem-hydrolyzing activity. 
1024    Current Drug Targets, 2016, Vol. 17, No. 9 Naas et al. 
The continuously growing number of crystallographic 
structures available in the PDB (646 -lactamase structures 
are available to date, from which 269 class A -lactamase struc-
tures and only 20 class A carbapenemase structures), together 
with the molecular modelling and site-directed mutagenesis 
studies which are often associated with the structure determina-
tion, will provide essential information for understanding the 
subtle mechanistic details controlling the activity and selectivity 
in substrate hydrolysis, as well as the inhibition of class A car-
bapenemases. As our image of this process will become more 
and more clear, the design of new classes of efficient antibiotics 
and -lactamase inhibitors will be facilitated, bringing some 
hope in our fight against antibiotic resistance. 
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